Treatment of Menopause in Postmenopausal Osteoporosis or Increased Risk of Osteoporosis / Fracture
In postmenopausal women with established osteoporosis — or a clinical profile placing them at elevated fracture risk — pharmacologic management is a treatment priority alongside broader menopausal care. The key clinical goals are prevention of bone loss and reduction of fracture risk.
Clinical Scenario
This protocol targets postmenopausal women in whom osteoporosis or increased fracture risk has been identified. Bone protection is an explicit treatment objective in this population, requiring a structured pharmacologic approach.
Treatment Approach (Partial Overview)
Management is pharmacologic and draws from several distinct drug classes — including hormone-based therapy and dedicated bone-targeted agents. The appropriate option for a given patient depends on individual clinical factors.
The complete regimen, agent selection criteria, and administration details are available in the full protocol below.
References
- Reduction in fracture risk in women at increased risk of osteoporosis or fracture
- Prevention of bone loss
- Therapeutic options include MHT (in appropriately selected patients), bisphosphonates, SERMs (raloxifene), RANK-ligand inhibitors (denosumab), or parathyroid hormone (teriparatide).
- oral alendronate (daily, weekly), risedronate (daily, weekly, monthly)
- zoledronic acid (yearly IV)
- denosumab (subcutaneous injection every 6 months)
- teriparatide (daily subcutaneous injection)
- raloxifene (oral)
View source ↗